Live Breaking News & Updates on Nagoya University In Aichi

Stay updated with breaking news from Nagoya university in aichi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials


Credit Justin Hicks / IPB News
Clinical trials for antiviral drugs to treat COVID-19 have produced inconsistent results. New research led by Indiana University says the problem may come down to how these trials are designed. 
Indiana University assistant research scientist Keisuke Ejima and researchers at Nagoya University in Aichi, Japan, created simulations based on clinical data to analyze how COVID-19 drug trials are designed. 
To best decrease the viral load, or the amount of virus in a person, the study found participants needed antiviral medication within two days of developing symptoms. But clinical trials on average get participants around five days after symptoms. ....

Justin Hicks , Keisuke Ejima , Indiana University , Nagoya University In Aichi , Nagoya University , ஜஸ்டின் ஹிக்ஸ் , இந்தியானா பல்கலைக்கழகம் , நாகோயா பல்கலைக்கழகம் ,

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials
wbaa.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wbaa.org Daily Mail and Mail on Sunday newspapers.

Keisuke Ejima , Indiana University , Nagoya University In Aichi , Nagoya University , இந்தியானா பல்கலைக்கழகம் , நாகோயா பல்கலைக்கழகம் ,

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials


New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials
Unable to load the audio player.
playpausemuteunmute
Article origination IPBS-RJC
To best decrease the viral load, or the amount of virus in a person, the study found participants needed antiviral medication within two days of developing symptoms.
Justin Hicks/IPB News
Clinical trials for antiviral drugs to treat COVID-19 have produced inconsistent results. New research led by Indiana University says the problem may come down to how these trials are designed. 
Indiana University assistant research scientist Keisuke Ejima and researchers at Nagoya University in Aichi, Japan, created simulations based on clinical data to analyze how COVID-19 drug trials are designed.  ....

Keisuke Ejima , Justin Hicks , Indiana University , Nagoya University In Aichi , Nagoya University , ஜஸ்டின் ஹிக்ஸ் , இந்தியானா பல்கலைக்கழகம் , நாகோயா பல்கலைக்கழகம் ,

Study reveals contributing factor to inconsistent results in clinical trials for COVID-19 drugs


Study reveals contributing factor to inconsistent results in clinical trials for COVID-19 drugs
Jul 8 2021
A new study suggests that significant variation in the amount of virus from person to person may be a contributing factor to inconsistent findings reported in clinical trials for antiviral COVID-19 drugs. The study is led by Keisuke Ejima, an assistant research scientist at the Indiana University School of Public Health-Bloomington.
A new study suggests that significant variation in the amount of virus from person to person may be a contributing factor to inconsistent findings reported in clinical trials for antiviral COVID-19 drugs. Photo courtesy of Getty Images ....

Shingo Iwami , Shoya Iwanami , Keisuke Ejima , Research Scientist , Indiana University School Of Public Health , Nagoya University In Aichi , Indiana University School , Nagoya University , Assistant Research Scientist , ஷிங்கோ இவமி , ஆராய்ச்சி விஞ்ஞானி , இந்தியானா பல்கலைக்கழகம் பள்ளி ஆஃப் பொது ஆரோக்கியம் , இந்தியானா பல்கலைக்கழகம் பள்ளி , நாகோயா பல்கலைக்கழகம் , உதவியாளர் ஆராய்ச்சி விஞ்ஞானி ,